Top news of the week: 20.10.2020.
#genetherapy #Biotech #SPAC #AAV #CambMA #COVID19
Startups
RT @JFruehauf: Exciting news this morning as @labcentral startup @Dyno_Tx announces big $1.8bn partnership with our founding sponsor @Roche.
Dyno has a unique #AAV platform for delivery of #genetherapy. Read more here:
https://t.co/6il8lQ1IOG
OpenDyno, Roche to tackle CNS, liver disease in gene therapy deal worth up to $1.8B
Potential partners have approached Cambridge-based Dyno Therapeutics since its founding two years ago to get in on the action. Today, Dyno announced its third partnership in the last five ...
RT @LifeSciVC: It’s Raining Biotech SPACs!
But why? They aren't for everyone, but there are some real benefits of SPACs for both sponsors and merger targets. #SPAC #Biotech
https://t.co/A1j5qPeDeW
OpenIt’s Raining Biotech SPACs!
SPACs are all the rage today. With the IPO market booming and public investors seeking better returns, blank check companies called “Special Purpose Acquisition Companies” (SPACs) have been ...
RT @HankGreelyLSJU: I've got a fun piece in @statnews First Opinions on Oct-Dec 1980: 2 months that shaped biotech. https://t.co/oo5jhLy0wt Five big things happened in 59 days. Is it meaningful or coincidence? I don't know. Is it important? Probably not, but I think it's interesting. You might, too.
OpenThe two months in 1980 that shaped the future of biotech
Five events in a two-month span in 1980 propelled the nascent biotech industry and university biotech research into the future.
.@OriBiotech raises $30 M in Financing. The new funding will help take their manufacturing platform to the market that delivers solutions to address the clinical and commercial manufacturing needs of cell and #genetherapy developers. Learn more: https://t.co/3KDStJHa7A https://t.co/FryA7W3zq3
OpenOri Biotech Raises $30 Million in Financing
Funds will be used to advance innovation in cell and gene therapy manufacturing.
Lilly wagers $135M on a startup's plan to stop neurodegeneration https://t.co/18u02uEt8V $LLY @atlasventure @DisarmTx
OpenLilly wagers $135M on a startup's plan to stop neurodegeneration
The drugmaker is acquiring Disarm Therapeutics, which was formed based on research into a specific enzyme's central role in the breakdown of axons.
Several companies have crammed multiple venture financings into a single year this year.
https://t.co/vJPw14G4zK
OpenHow some biotechs are cramming multiple fundraising rounds into a single year
Some biotechs crammed multiple venture financings into a single year this year or even managed to go public less than 18 months after launch.
"At this point, there are only two (#COVID19) vaccine candidates that could meet this deadline (end of 2020): @Pfizer's & @BioNTech's jointly produced BNT162b2 and @Moderna's mRNA-1273." https://t.co/EklERipQdq
OpenHere Are the Only 2 Coronavirus Vaccines That Could Meet the FDA's Authorization Guidelines by Year-End
It's a process of elimination.
RT @atlasventure: We are delighted to welcome Aimee Raleigh to the Atlas Venture investment team today! Learn more about Aimee here: https://t.co/EwVJd0LM83 https://t.co/ZYtpSiP9NW
OpenAimee Raleigh, PhD, Associate
Aimee Raleigh is an associate at Atlas Venture where she focuses on evaluating innovative technologies for therapeutic potential in areas of high unmet need. Prior to joining Atlas, Aimee ...